SML2913
Dehydroxylcannabidiol
≥98% (HPLC)
Synonim(y):
2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentylphenol, DH-CBD
Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.
Wybierz wielkość
Zmień widok
Informacje o tej pozycji
Wzór empiryczny (zapis Hilla):
C21H30O
Numer CAS:
Masa cząsteczkowa:
298.46
NACRES:
NA.77
UNSPSC Code:
12352200
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomócQuality Level
assay
≥98% (HPLC)
form
oil
optical activity
[α]/D -135 to -120°, c = 0.5 in chloroform-d
color
colorless to light brown
storage temp.
2-8°C
Biochem/physiol Actions
Dehydroxylcannabidiol (DH-CBD) is a synthetic nonpsychoactive cannabinoid that alleviate acute pain and chronic inflammatory pain by targeting α3 GlyRs. Dehydroxylcannabidio restores the function of both hyperekplexic mutant GlyRα1 and GABAAR in the presence of GlyRα1R271Q. Apparently dehydroxylcannabidiol interrupts the protein interaction GlyRα1 and GABAAR.
Synthetic nonpsychoactive cannabinoid that alleviate acute pain and chronic inflammatory pain by targeting α3 GlyRs
Ta strona może zawierać tekst przetłumaczony maszynowo.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Repr. 2
Klasa składowania
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Wybierz jedną z najnowszych wersji:
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Jieping Lu et al.
Neuropharmacology, 133, 224-232 (2018-02-07)
Some cannabinoids have been shown to suppress chronic pain by targeting glycine receptors (GlyRs). Although cannabinoid potentiation of α3 GlyRs is thought to contribute to cannabinoid-induced analgesia, the role of cannabinoid potentiation of α1 GlyRs in cannabinoid suppression of chronic
Wei Xiong et al.
The Journal of experimental medicine, 209(6), 1121-1134 (2012-05-16)
Certain types of nonpsychoactive cannabinoids can potentiate glycine receptors (GlyRs), an important target for nociceptive regulation at the spinal level. However, little is known about the potential and mechanism of glycinergic cannabinoids for chronic pain treatment. We report that systemic
Guichang Zou et al.
The Journal of biological chemistry, 295(1), 138-145 (2019-11-24)
The functions of the glycine receptor (GlyR) and GABAA receptor (GABAAR) are both impaired in hyperekplexia, a neurological disorder usually caused by GlyR mutations. Although emerging evidence indicates that cannabinoids can directly restore normal GlyR function, whether they affect GABAAR
Numer pozycji handlu globalnego
| SKU | NUMER GTIN |
|---|---|
| SML2913-5MG | 04061841806622 |
| SML2913-25MG | 04061841806615 |